News | PET-CT | October 25, 2017

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria

New guidelines focus on appropriate imaging procedure for restaging and treatment response assessment of malignant disease

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria

October 25, 2017 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/CT (positron emission tomography/computed tomography) in restaging and treatment response assessment of malignant disease. As cancer patients move through therapy, FDG PET/CT has proven an effective tool for assessing treatment response and updating the stage of malignancy. This AUC aims to improve utilization and guide providers across specialties in its use. 

This is the fourth in a series of new AUC developed by SNMMI in its role as a qualified provider-led entity (PLE) under the Medicare Appropriate Use Criteria Program for Advanced Diagnostic Imaging. The society’s other recently released AUC are for bone scintigraphy in prostate and breast cancerventilation/perfusion (V/Q) imaging in pulmonary embolism, which is endorsed by the American College of Emergency Physicians; and hepatobiliary scintigraphy in abdominal pain.  

The new AUC are intended to assist referring physicians and ordering professionals in fulfilling the requirements of the 2014 Protecting Access to Medicare Act (PAMA). Current regulations call for PAMA to require referring physicians to consult AUC developed by a PLE beginning Jan. 1, 2018, to ensure cost-effective and appropriate utilization of advanced diagnostic imaging services. However, the Centers for Medicare & Medicaid Services has proposed pushing back the start date for when providers will be required to consult AUC to January 2019.

The FDG PET/CT Workgroup consisted of expert representatives from SNMMI, the European Association of Nuclear Medicine (EANM) and the American Society of Clinical Oncology (ASCO). They reviewed the scientific literature and developed consensus recommendations for the clinical use of this technology. The Oregon Health Science University's (OHSU) Evidence-based Practice Center conducted a systematic review of existing evidence based on the scope and parameters the PET/CT Workgroup put together, which they used to make their recommendations for clinical use.

The SNMMI Guidance Oversight Committee is also developing AUC for gastrointestinal transit, infection imaging, PET myocardial perfusion imaging, prostate cancer imaging, somatostatin imaging, and thyroid imaging and therapy. 

The full AUC can be viewed here. An abbreviated version of the AUC will be published in the December 2017 issue of The Journal of Nuclear Medicine and is available online ahead of print.

For more information: www.snmmi.org

Related Content

News | Clinical Decision Support | January 12, 2018
January 12, 2018 — GE Healthcare has entered into a strategic, long-term partnership with Roche to jointly develop an
State-of-the-Art MRI Technology Bypasses Need for Biopsy
News | Magnetic Resonance Imaging (MRI) | January 09, 2018
January 9, 2018 – The most common type of tumor found in the kidney is generally quite small (less than 1.5 in).
Imagio Opto-Acoustic Breast Imaging System Helps Differentiate Tumor Subtypes
News | Oncology Diagnostics | January 02, 2018
Seno Medical Instruments Inc. (Seno Medical) recently reported data from their clinical study demonstrating that its...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Mirada Medical and Optellum Debut AI-Based Lung Cancer Diagnosis Solution at RSNA 2017
News | Computed Tomography (CT) | December 14, 2017
Optellum, a high-tech startup in lung cancer and machine learning, and Mirada Medical recently announced a partnership...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Light and Ultrasound Waves Allow More Precise Excision of Skin Cancer Tumors

3-D MSOT rendering of a basal cell carcinoma. Image courtesy of Singapore BioImaging Consortium

News | Oncology Diagnostics | November 20, 2017
Scientists and clinicians from Singapore and Germany have successfully used multispectral optoacoustic tomography (MSOT...
HealthMyne Highlights Value of Quantitative Data in Oncology Reads at RSNA 2017
News | Clinical Decision Support | November 17, 2017
November 17, 2017 — At the 2017 Radiological Society of North America (RSNA) conference, HealthMyne will demonstrate
Biop Medical Launches Cervical Cancer Diagnosis Technology at MEDICA 2017

Biop Medical cervical cancer detection system

Technology | Women's Health | November 13, 2017
November 13, 2017 — Biop Medical announced it will present its point-of-care...
Overlay Init